New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Patient age should play a role in drug development strategies for melanoma, researchers of a new study say.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Paul Nghiem, MD, PhD, discusses his findings at the ASCO 2018 meeting.
Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.
When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.
Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.
Victor Sandor, MD, discusses the treatment combination at the ASCO 2018 meeting in Chicago.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Married people are more likely than unmarried, divorced, or widowed patients to be diagnosed with skin cancer at early, more readily-treatable stages of disease.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
The FDA based its approval on the results of the phase 3 COMBI-AD study.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
KEYNOTE-054 may show whether some patients with resected disease can forego adjuvant therapy.
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
Improvement in RFS was seen regardless of PD-L1 status.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
Grade 3 to 4 adverse events were observed in 54% (19), 16% (4), and 13% (2) of patients in Cohorts A, B, and C, respectively.
This systematic review analyzed the current evidence on the benefits and harms of behavioral counseling for skin cancer prevention and found that these interventions can increase sun protection behavior.
One death possibly related to treatment was, however, noted in the combination group.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Researchers randomly assigned 129 patients with previously untreated metastatic uveal melanoma to receive dacarbazine plus selumetinib or placebo.
A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
- Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
- FDA Updates Restrictions for Pembrolizumab, Atezolizumab in Urothelial Carcinoma
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer